About Us

Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK. We are committed to transforming the discovery of treatments for neurodegenerative disease, with a focus in dementia. Our novel human stem cell models of dementia provide a transformative platform for rapid and relevant target identification and validation, significantly accelerating drug discovery. Talisman’s primary goal is the exploitation of these systems to identify novel pharmacological treatments for neurodegenerative diseases, including Alzheimer’s disease, through our external collaborative work and through our in-house drug discovery programme.

Background

Talisman Therapeutics’ primary intellectual property is informed by the work of founding scientist Prof Rick Livesey, University College London. The company was established on the Babraham Campus in Cambridge in 2014 and is privately held. The company has grown organically since its launch and now collaborates with many organisations around the world – including blue chip global pharmaceutical companies, small local biotechnology companies and academic departments. In 2017, Talisman doubled the size of its labs in Babraham. All of the science staff are PhD level and above.

How We Work

There is an immediate unmet need for the development of new treatments that target the underlying causes of Alzheimer’s disease and other dementias, allowing early intervention before irreversible changes occur. Meeting this need is the focus of Talisman’s work and we do this by collaborating with external organisations and by undertaking research through our in-house drug-discovery programmes.

In-house drug discovery programmes

We have a number of ongoing internal research programmes

Collaborations with global pharma and biotech companies

We collaborate with other organisations to assist with their drug discovery efforts. Partners include large pharmaceutical companies, small biotech businesses and universities. We do this on a shared-equity or on a fee-for-service basis.

Read more about why pharma and biotech companies collaborate with Talisman